Overview of the MacroGenics Lawsuit
The MacroGenics class action lawsuit represents individuals who acquired MacroGenics, Inc. (NASDAQ: MGNX) securities between March 7, 2024, and May 9, 2024, the designated class period. Officially titled Crain v. MacroGenics, Inc., No. 24-cv-02184 (D. Md.), this litigation alleges violations of the Securities Exchange Act of 1934 by MacroGenics and its Chief Executive Officer, Scott Koenig.
If you experienced losses from investing in MacroGenics stock during the class period, you may be eligible to participate in the MacroGenics class action lawsuit. Contact securities fraud attorney Timothy L. Miles at no cost to discuss your potential role and rights as a shareholder by calling 855-846-6529, emailing [email protected], or filling out an online contact form. Investors have until September 24, 2024, to file motions seeking appointment as the lead plaintiff in the MacroGenics class action lawsuit. Acting as the lead plaintiff enables you to direct the litigation and decision-making processes on behalf of the class. Allegations Driving the MacroGenics class action Lawsuit
MacroGenics, a biopharmaceutical firm specializing in cancer treatments, recently disclosed interim findings from its TAMARACK Phase 2 clinical trial of vobramitamab duocarmazine (vobra duo), a monoclonal antibody-based therapeutic. These revelations have significant implications for investors and form the basis of the MacroGenics class action lawsuit allegations:
Study Overview
The TAMARACK study evaluated two dosage levels of vobra duo for treating metastatic castration-resistant prostate cancer (mCRPC):
Key Findings Unveiled on May 9, 2024
MacroGenics presented updated safety and efficacy data, revealing concerning statistics:
Market Impact
The release of these findings had an immediate and substantial effect on MacroGenics' stock price, with shares plummeting by more than 77%. This sharp decline reflects investor concerns about vobra duo's safety profile and its potential future in the market.
Implications for Investors
Lead Plaintiff Deadline for the MacroGenics Lawsuit
Investors have until September 24, 2024, to file motions seeking appointment as the lead plaintiff in the MacroGenics class action lawsuit. When a securities class action is filed:
The Lead Plaintiff Process in the MacroGenics class action lawsuit
Under the Private Securities Litigation Reform Act of 1995 (PSLRA):
Benefits of Serving as the Lead Plaintiff
Acting as the lead plaintiff in the MacroGenics class action lawsuit offers several advantages:
Responsibilities of the Lead Plaintiff
The lead plaintiff in the MacroGenics class action lawsuit will assume the following responsibilities:
Eligibility Criteria for Lead Plaintiff Appointment
To be eligible for appointment as the lead plaintiff in the MacroGenics class action lawsuit, an investor must meet the following criteria:
Legal Requirements for Prevailing in the Lawsuit
To succeed in the MacroGenics class action lawsuit, the plaintiffs must establish the following elements:
Stages of the MacroGenics Class Action Lawsuit
Securities class action lawsuits typically follow a multi-stage process, which may include:
Contingency Fee Arrangements and Cost Considerations
Many securities litigation attorneys, including Timothy L. Miles, operate on a contingency fee basis, which means clients do not pay any upfront fees or costs.
CONTACT MACROGENICS STOCK LOSS LAWYER TODAY TIMOTHY L MILES TODAY ABOUT A MACROGENICS CLASS ACTION LAWSUIT
If you suffered losses in MacroGenics stock, contact MacroGenics stock loss lawyer Timothy L. Miles today for a free case evaluation about a MacroGenics class action lawsuit. Call today and see what a MacroGenics stock loss lawyer could do for you if you suffered losses in MacroGenics stock. This will most likely be the only call you need to make. (855) 846–6529 or [email protected].
The Law Offices of Timothy L. Miles
Tapestry at Brentwood Town Center 300 Centerview Dr., #247 Brentwood, TN 37027 Phone: (855) 846–6529 Email: [email protected] MACROGENICS STOCK LOSS LAWYER TIMOTHY L. MILES Nashville attorney Timothy L. Miles is a nationally recognized shareholder rights attorney raised in Nashville, Tennessee. Mr. Miles has dedicated his career to representing shareholders, employees, and consumers in complex class-action litigation. Whether serving as lead, co-lead, or liaison counsel, Mr. Miles has helped recover hundreds of millions of dollars for defrauded investors, shaped precedent-setting decisions, and delivered real corporate governance reforms. Judges and peers have repeatedly recognized Mr. Miles’ relentless advocacy for the underdog, as well as his unbendable ethical standards. Mr. Miles was recently selected by Martindale-Hubbell® and ALM as a 2022 Top Ranked Lawyer, 2022 Top Rated Litigator. and a 2022 Elite Lawyer of the South. Mr. Miles also maintains the AV Preeminent Rating by Martindale-Hubbell®, their highest rating for both legal ability and ethics. Mr. Miles is a member of the prestigious Top 100 Civil Plaintiff Trial Lawyers: The National Trial Lawyers Association,Class Action: Class Action: Top National Trial Lawyers, National Trial Lawyers Association (2023), a superb rated attorney by Avvo, a recipient of the Lifetime Achievement Award by Premier Lawyers of America (2019) and recognized as a Distinguished Lawyer, Recognizing Excellence in Securities Law, by Lawyers of Distinction (2019); a Top Rated Litigator by Martindale-Hubbell® and ALM (2019-2022); America’s Most Honored Lawyers 2020 – Top 1% by America’s Most Honored (2020-2022). Mr. Miles has published over sixty articles on various issues of the law, including class actions, whistleblower cases, products liability, civil procedure, derivative actions, corporate takeover litigation, corporate formation, mass torts, dangerous drugs, and more. Please visit our website or call for free anytime. Comments are closed.
|
AuthorTimothy L. Miles Archives
November 2024
Categories
All
|
HoursSITEMAP
|
|